Overview
- The direct antiglobulin test (DAT), or Coombs test, introduced in 1945, is one of the most diagnostically powerful assays in transfusion medicine and clinical haematology.
- It detects immunoglobulins and/or complement components bound to red blood cells (RBCs) in vivo, exploiting antihuman globulin (AHG) reagents, antibodies raised against human immunoglobulins or complement components, produced either by animal immunisation or hybridoma technology, to bridge antibody-coated RBCs and produce visible agglutination.
- The DAT must be distinguished from the indirect antiglobulin test (IAT).
- The DAT interrogates the patient's own circulating RBCs for in vivo sensitisation; the IAT detects antibodies free in the patient's serum or plasma by incubating them with reagent RBCs in vitro, then detecting bound antibody with AHG after washing.
- The IAT is used for antibody screening, antibody identification, crossmatching, and antigen phenotyping.
Clinical indications for the DAT:
| Clinical Indication | Expected Mechanism |
|---|---|
| Warm autoimmune haemolytic anaemia (wAIHA) | IgG autoantibody ± complement on RBC surface |
| Cold agglutinin disease (CAD) | Complement (C3d) deposition; IgM rarely detected ex vivo |
| Mixed-type AIHA | IgG + IgM + C3d |
| Haemolytic disease of the fetus and newborn (HDFN) | Maternal IgG alloantibody coating fetal RBCs |
| Delayed or acute haemolytic transfusion reaction | IgG alloantibody against donor RBC antigen |
| Drug-induced immune haemolysis | Drug-dependent antibody or non-immunological protein adsorption |
Antihuman Globulin Reagents
Polyspecific (Broad-Spectrum) Reagents
- Polyspecific AHG reagents contain antibodies directed against both human IgG and complement components.
- They are the standard first-line reagent for DAT screening.
Essential components:
| Component | Rationale |
|---|---|
| Anti-IgG (anti-γ heavy chain) | Vast majority of clinically significant alloantibodies and autoantibodies are IgG; essential for detection |
| Anti-C3d | Detects complement-coated RBCs; critical where IgM has dissociated (e.g. CAD) |
| Anti-C3c | Detects early complement fragments; contributes to sensitivity |
Components not required in polyspecific reagents:
- Anti-IgA: IgA antibodies of the same specificity virtually always co-exist with IgG antibodies; detection via anti-IgG suffices. The rare IgA-only AIHA (prevalence 0.2-2.7%) requires dedicated monospecific anti-IgA.
- Anti-IgM: Clinically significant IgM alloantibodies that do not agglutinate saline-suspended cells are more readily detected via the complement they activate. IgM dissociates from the RBC surface at 37 °C and is rarely found attached ex vivo.
- Anti-C4: Should be present at only low or absent levels. Excess anti-C4 causes false-positive reactions because C4 can non-specifically adsorb onto stored donor RBCs.
- Effect of sample type: When plasma collected in EDTA is used, an anti-IgG-only reagent suffices, because EDTA chelates Ca²⁺ and Mg²⁺, preventing in vitro complement activation.
- Anti-C3 remains essential for DATs performed for AIHA diagnosis regardless of technique.
- IAT reagent practice: The IAT typically uses monospecific anti-IgG alone.
- AABB guideline changes (1990) and BCSH guideline changes (1996) supported anti-IgG-alone for IAT in laboratories using techniques other than normal-ionic-strength saline (NISS); however, BCSH guidelines stress the importance of using screening cells with homozygous expression of Jk^a before abandoning polyspecific reagent for the IAT.
Monospecific Reagents
- Monospecific AHG reagents contain a single antibody specificity.
- Their primary application is to characterise the immunochemical nature of a positive DAT, determining whether IgG, a specific IgG subclass, or a complement component is responsible, which informs the mechanism of in vivo cell destruction.
Available monospecific reagents:
| Reagent | Target | Key Application |
|---|---|---|
| Anti-IgG (anti-γ) | IgG heavy chain | Confirm IgG-mediated sensitisation; wAIHA |
| Anti-IgA (anti-α) | IgA heavy chain | Detect rare IgA-only AIHA |
| Anti-IgM (anti-μ) | IgM heavy chain | Detect IgM in gel/column methods (not reliably in tube) |
| Anti-C3d | C3d fragment | Complement deposition; CAD, mixed AIHA |
| Anti-C3c | C3c fragment | Earlier complement fragment |
| Anti-C3b | C3b fragment | Active complement fixation |
| Anti-C4b/C4d | C4 fragments | Not routine; used in QC validation |
| Anti-IgG subclass (IgG1-4) | Individual subclasses | Characterise pathogenic potential; IgG1/IgG3 most haemolytic |
Interpretation of monospecific DAT panel:
| DAT Pattern | Typical Association |
|---|---|
| IgG only | wAIHA; drug-induced (hapten or true autoantibody mechanism); alloantibody (transfusion reaction, HDFN) |
| IgG + C3d | wAIHA with complement activation; generally more aggressive haemolysis |
| C3d only | CAD (IgM eluted during washing, C3d remains); paroxysmal cold haemoglobinuria |
| IgM + C3d | Cold AIHA (gel methods required to retain IgM) |
| IgG + IgM + C3d | Mixed-type AIHA |
| IgA (polyspecific negative) | Rare IgA-only AIHA; requires monospecific anti-IgA |
- IgG subclass data inform pathophysiology: IgG1 and IgG3 bind Fcγ receptors on macrophages and activate complement most efficiently, correlating with more severe extravascular haemolysis.
- IgG4 autoantibodies are rarely haemolytic.
Methodology
Tube (Spin-Tube) Technique
The classical and historically standard technique, recommended by BCSH guidelines.
- Wash patient RBCs three to four times with large volumes of normal saline to remove all free plasma proteins (unbound IgG), which would neutralise AHG and produce false-negative results. This step is critical. Glass tubes are preferred over plastic, as plastic can adsorb IgG from the reagent.
- Add AHG reagent (polyspecific or monospecific) to the washed cell button (2 volumes of AHG per test; avoid prozone by not exceeding recommended volumes).
- Centrifuge briefly (typically 10-60 seconds at approximately 1000 × g).
- Resuspend gently and examine macroscopically (concave mirror, good illumination), then microscopically for all negative results.
- Add IgG-sensitised check cells (IgG-coated RBCs) to all negative tests to confirm the AHG reagent was active and not neutralised, a negative result with failed check cells is invalid.
- Detection threshold (tube method): approximately 150-300 IgG molecules per RBC (some sources cite up to 4000 molecules/RBC as the upper threshold for detection variability).
- This relative insensitivity is the principal limitation in DAT-negative AIHA.
Negative reactions should be further incubated at room temperature, then re-centrifuged and re-read, as additional incubation may promote complement-mediated positivity.
Column Agglutination Technology (Gel Cards)
- Microtubes filled with a gel or glass bead matrix are pre-loaded with AHG reagent.
- During centrifugation, unagglutinated cells pass to the microtube tip; agglutinates are trapped in the matrix.
| Feature | Tube Method | Gel/Column Method |
|---|---|---|
| Washing step | Required (3-4 manual washes) | Not required |
| Sensitivity | ~150-300 IgG molecules/RBC | Greater sensitivity |
| Low-affinity antibody detection | Poor (eluted during washing) | Superior |
| IgA/IgM AIHA detection | Often missed | Detectable with monospecific cards |
| Standardisation | Operator-dependent | High standardisation |
| Check cells | Required for all negatives | Not required |
- The DiaMed DAT gel card contains monospecific reagents (anti-IgG, anti-IgA, anti-IgM, anti-C3c, anti-C3d, inert control) in individual microtubes.
- Because there is no washing phase, low-affinity antibodies and rare entities such as IgA-only AIHA are detectable.
Enhanced Sensitivity Techniques
For DAT-negative AIHA with clinical evidence of haemolysis:
| Technique | Approximate Detection Threshold | Comment |
|---|---|---|
| Standard tube | 150-300 IgG/RBC | Baseline |
| Column agglutination | Greater sensitivity than tube | First-line alternative |
| Flow cytometry | ~30-40 IgG/RBC | Quantitative; reference laboratory |
| ELISA (enzyme-linked antiglobulin test) | ~8-30 IgG/RBC | Reference laboratory |
| PVP/polybrene-enhanced tube | ~8 IgG/RBC | Rarely routine |
| PVP + bromelin | ~1-3 IgG/RBC | Research |
| Radioimmune assay (¹²⁵I anti-IgG) | Very high sensitivity | Historical/research |
DAT-Negative AIHA
Approximately 2-6% of patients with clinical and haematological features of AIHA have persistently negative DATs by routine polyspecific testing. Mechanisms include:
- Low-affinity IgG autoantibodies: dissociate from RBCs during the washing phase of the tube technique.
- Subthreshold IgG density: insufficient IgG molecules per RBC to produce agglutination (threshold 300-4000 molecules/RBC with tube technique).
- IgA-only AIHA: prevalence 0.2-2.7%; polyspecific reagents have little anti-IgA activity.
- IgG subclass not detected: subclass-specific limitations of the AHG reagent used.
Management approach: If polyspecific DAT is negative with compelling clinical evidence of haemolysis (spherocytes on blood film, elevated LDH, low haptoglobin, reticulocytosis), proceed to:
- Column agglutination monospecific panel (gel card)
- Flow cytometric DAT
- ELISA
- Exclusion of other hereditary or acquired haemolytic causes before diagnosing DAT-negative AIHA
Causes of a Positive DAT
- A positive DAT does not automatically indicate active immune haemolysis.
- Interpretation requires clinical correlation.
| Cause | AHG Specificity | Clinical Context |
|---|---|---|
| wAIHA | IgG ± C3d | Haemolytic anaemia; spherocytes on film |
| Cold agglutinin disease | C3d (± IgM in gel) | Cold-triggered haemolysis; RBC agglutinates on film |
| Paroxysmal cold haemoglobinuria | C3d (biphasic IgG, Donath-Landsteiner) | Acute intravascular haemolysis post-viral illness |
| Mixed AIHA | IgG + IgM + C3d | Severe haemolysis |
| Delayed haemolytic transfusion reaction | IgG | Post-transfusion haemolysis; new alloantibody |
| HDFN | IgG | Neonatal jaundice, anaemia |
| Drug-induced haemolysis (true autoantibody, e.g. methyldopa) | IgG | Drug history; pan-reactive eluate |
| Drug-induced haemolysis (hapten mechanism, e.g. penicillin) | IgG | Eluate reacts only with drug-coated cells |
| Non-immunological protein adsorption (e.g. some cephalosporins) | IgG (non-specific) | Positive DAT; no haemolysis; negative eluate |
| Complement activation without haemolysis | C3d | Hypergammaglobulinaemia, chronic inflammation |
| Positive in healthy individuals | IgG (low level) | Incidence 1:100 to 1:15,000; low-avidity non-specific adsorption |
False-Positive and False-Negative DAT Results
False-Positive Causes
- Inadequate washing, residual free serum IgG neutralises AHG before reacting with cell-bound antibody
- Excess anti-C3d in reagent detecting C3d on stored donor RBCs (particularly after incubation with fresh serum)
- Non-specific protein adsorption (hypergammaglobulinaemia, SLE, B-cell malignancies)
- Bacterial contamination of reagents or sample
- Wharton's jelly contamination in neonatal cord blood samples
False-Negative Causes
- Insufficient or inadequate washing (paradoxically, residual plasma proteins neutralise AHG)
- Impotent or outdated AHG reagent
- Low-affinity antibody eluted during washing
- RBC-bound antibody below tube detection threshold
- IgA-only or IgM-only sensitisation not detected by polyspecific reagent
- Antibody of IgG subclass not detected by the AHG reagent used
Elution
- When the DAT is positive, elution studies recover and characterise the antibody bound to the RBC surface.
- The eluate is then tested against a panel of group O reagent RBCs by IAT to define antibody specificity.
Principle
Elution techniques reverse or neutralise the forces binding antibody to RBC antigen, releasing the antibody in a concentrated, identifiable form free from interfering plasma antibodies.
Elution Methods
| Method | Mechanism | Best Application |
|---|---|---|
| Heat elution (56 °C) | Thermal disruption of antibody-antigen bonds | Cold-reactive IgM antibodies (anti-A, anti-B, anti-I, anti-M, anti-N); ABO-HDFN |
| Lui freeze-thaw | Membrane disruption releases bound antibody | ABO-HDFN investigation |
| Acid elution (pH alteration) | Protonation disrupts antigen-antibody binding | IgG antibodies; wAIHA; commercially available kit-based methods; safer than organic solvents |
| Organic solvent (ether/chloroform, historical) | Solvent disruption of lipid membrane and antibody binding | IgG antibodies; largely superseded due to safety and availability |
| Digitonin-acid method | Combined membrane perturbation and pH change | IgG alloantibodies and autoantibodies |
Practical guidance:
- Acid elution kits (commercial pH-based preparations) are the most widely used contemporary technique, effective, standardised, and free from the hazards of organic solvents.
- Heat elution at 56 °C is preferred for ABO-HDFN investigation (elutes anti-A and anti-B from neonatal RBCs) and cold-reactive IgM antibodies.
- The Lui freeze-thaw method is an alternative specifically for ABO-HDFN.
Eluate Interpretation
| Pattern | Interpretation |
|---|---|
| Pan-reactive (all panel cells positive) | Autoantibody (e.g. wAIHA) with no discernible specificity, or high-prevalence antigen alloantibody |
| Specific reactivity | Alloantibody (e.g. anti-E, anti-K, anti-Jk^a), confirms alloimmune process (delayed transfusion reaction or HDFN) |
| Non-reactive (negative) | Non-immunological protein adsorption; or bound antibody is not IgG (e.g. IgA); or low-affinity antibody lost during elution |
Quality Control of AHG Reagents
| QC Element | Standard |
|---|---|
| Anti-IgG potency | Titration against IgG-sensitised RBCs (weak IgG anti-D, R₁r cells, diluted neat to 1:16); must meet or exceed current reference reagent |
| Specificity (anti-C3d) | Must not agglutinate unsensitised cells; no excess anti-C3d causing false positives with stored donor RBCs incubated with fresh serum |
| Freedom from contaminating alloantibodies | Must not react with washed A₁, B, or O cells |
| Anti-C4 content | Should contain little or no anti-C4 to avoid false positives |
| Prozone testing | Should not demonstrate prozone at recommended volumes (2 volumes AHG per test) |
| Check cells | IgG-sensitised RBCs added to all negative tube DATs to confirm AHG reagent activity |
| ISBT/ICSH reference reagent | Freeze-dried reference standard available for calibration of polyspecific or monospecific components |
- Validation of a new AHG reagent must assess: specificity; potency of anti-IgG by serological titration; and specificity and potency of anticomplement antibodies.
- The assessment requires RBCs specifically coated with C3b, C3bi, C3d, and C4.
- Quality control of the reagent must be carried out using the exact technique by which it will be used in practice.
Diagnostic Application in AIHA, Step-Wise DAT Approach
$$\text{Step 1: Polyspecific DAT} \rightarrow \text{positive or negative}$$
$$\text{Step 2: Monospecific panel (anti-IgG, anti-C3d, anti-IgA, anti-IgM)} \rightarrow \text{defines immunochemical pattern}$$
$$\text{Step 3: Eluate study} \rightarrow \text{defines antibody specificity}$$
| Step | Reagent | Purpose |
|---|---|---|
| 1 | Polyspecific AHG | Screening, detects IgG and/or complement |
| 2a | Monospecific anti-IgG | Confirms IgG coating |
| 2b | Monospecific anti-C3d | Confirms complement deposition |
| 2c | Monospecific anti-IgA | Detects rare IgA-only AIHA |
| 2d | Monospecific anti-IgM | Detects IgM in gel-based systems |
| 3 | Elution + panel IAT | Characterises antibody specificity in eluate |
Special Considerations
Neonatal/Cord Blood
- Wharton's jelly causes false-positive DATs; thorough washing of cord RBCs is essential.
- A positive DAT (IgG) in neonatal jaundice and anaemia confirms alloimmune haemolysis (HDFN).
Evans Syndrome
- Simultaneous AIHA and immune thrombocytopenia; DAT typically positive (IgG ± C3d).
- May signal common variable immunodeficiency or primary immunodeficiency syndrome (especially in children).
- Evans syndrome indicates high-risk disease.
Drug-Induced Immune Haemolysis
- True autoantibody induction (e.g. methyldopa, fludarabine): DAT positive with IgG; eluate pan-reactive.
- Hapten mechanism (e.g. penicillin, high-dose): DAT positive with IgG; eluate reactive only with drug-coated cells.
- Non-immunological protein adsorption (e.g. some cephalosporins): DAT positive; no haemolysis; eluate negative.
Positive DAT in Healthy Individuals
- Incidence 1:100 to 1:15,000 depending on technique.
- Most attributable to low-avidity non-specific IgG adsorption.
- A positive DAT in isolation, without evidence of haemolysis, must not be misinterpreted as AIHA.
EDTA Sample Requirement
- Patient RBCs for DAT should be collected in EDTA.
- EDTA chelates divalent cations (Ca²⁺, Mg²⁺), preventing in vitro complement activation during sample processing and avoiding false-positive anti-C3 reactions.